The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 869 Weight Management articles
Groundbreaking research indicates that GLP-1 receptor agonists, widely recognized for their impact on diabetes and weight management, may also play a crucial role in modulating impulsive behaviors that can lead to criminal acts and violence.
Emerging research indicates that GLP-1 medications, including Ozempic and Mounjaro, may offer unexpected benefits for male reproductive health by addressing underlying metabolic issues.
Can GLP-1 medications like Ozempic or Wegovy improve male fertility? A new study indicates potential benefits for testosterone and sperm health, but what does this mean for patients?
A surge in injectable peptides marketed online for enhancement purposes is outpacing regulatory oversight, creating a 'grey zone' with potential public health implications. This article delves into the complexities, risks, and what consumers should understand.
While GLP-1 medications have revolutionized weight loss, a recent study indicates a concerning trend: users may be reducing their physical activity. This article explores the findings and emphasizes the continued importance of exercise.
Recent research highlights a potential safety concern with GLP-1 medications, linking them to an increased risk of dizziness and fainting, particularly in certain patient groups. Discover what this means for your health.
The advent of affordable, locally produced GLP-1 agonists in India marks a significant shift in managing the nation's escalating obesity crisis. For millions like Manoj, these once exclusive medications are now within reach, provided they adhere to strict medical guidance and lifestyle adjustments.
The booming popularity of GLP-1 medications for weight loss has coincided with a dramatic rise in telehealth services. This article delves into the benefits and significant risks of obtaining these powerful drugs online, highlighting critical safety concerns and offering guidance for patients.
New research presented at the American Diabetes Association meeting highlights the potential of combining cagrilintide, an amylin receptor agonist, with semaglutide for improved glycemic control in adults with type 2 diabetes.
